Medication info
Terna Tablet (Terbinafine Hydrochloride)

Terna Tablet (Terbinafine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
Withus Pharma Co., Ltd.
Appearance
White to nearly off-white round tablets
Packaging
30 tablets/bottle, 150 tablets/bottle
Approval status
Active

MFDS item code 200402824 · Notified 2004.11.19 · Insurance code 660701810

Summary

Main use
Treatment of onychomycosis and cutaneous mycoses (e.g., tinea pedis and tinea corporis), and tinea capitis
Who takes it
Adults · Children
Adult dose
Administer terbinafine at a dose of 125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually given for 6 weeks~3 months. In cases of infection of the fingernails or relatively small toenails, or in younger patients, the treatment period may be shortened to 3 months or less. A treatment period of 3 months is usually sufficient for toenail infections, but in some patients it may take 6 months or longer. The treatment period may be longer in patients with slow nail growth. In patients with a creatinine clearance of less than 50 mL per minute, reduce the daily dose by 1/2.
Child dose
Administer to children aged 2 years and older. Administration is not recommended in children under 2 years of age because there is no experience with its use. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of the infection, treatment should be administered regularly and appropriately for the prescribed duration. 1) Body weight under 20 kg (under 5 years): 62.5 mg per dose, administered once daily. Because there is limited experience with its use, the decision to administer should be made after considering the benefits and risks of treatment. 2) Body weight 20~40 kg (5 to 12 years): 125 mg per dose, administered once daily. 3) Body weight over 40 kg (over 12 years): 250 mg per dose, administered once daily.

Ingredients

Manufacturer
Withus Pharma Co., Ltd.

Efficacy & effects

Treatment of onychomycosis and cutaneous mycoses (e.g., tinea pedis and tinea corporis), and tinea capitis

  • Dermatophytosis
  • athlete's foot
  • body ringworm
  • jock itch
  • onychomycosis
  • tinea capitis
View approved original text

This medicine is used to treat dermatophytosis such as athlete's foot, body ringworm, and jock itch in adults, and it is also used to treat tinea capitis in children. It effectively improves fungal infections occurring on the skin or nails.

How to take

Adult dose

Administer terbinafine at a dose of 125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually given for 6 weeks~3 months. In cases of infection of the fingernails or relatively small toenails, or in younger patients, the treatment period may be shortened to 3 months or less. A treatment period of 3 months is usually sufficient for toenail infections, but in some patients it may take 6 months or longer. The treatment period may be longer in patients with slow nail growth. In patients with a creatinine clearance of less than 50 mL per minute, reduce the daily dose by 1/2.

Child dose

Administer to children aged 2 years and older. Administration is not recommended in children under 2 years of age because there is no experience with its use. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of the infection, treatment should be administered regularly and appropriately for the prescribed duration. 1) Body weight under 20 kg (under 5 years): 62.5 mg per dose, administered once daily. Because there is limited experience with its use, the decision to administer should be made after considering the benefits and risks of treatment. 2) Body weight 20~40 kg (5 to 12 years): 125 mg per dose, administered once daily. 3) Body weight over 40 kg (over 12 years): 250 mg per dose, administered once daily.

Precautions

This medication is not recommended for patients with liver problems. Liver function tests must be conducted before administration, and liver function should be regularly monitored during treatment. If any abnormal liver functions occur, the use of the medication should be stopped immediately. Symptoms such as nausea, loss of appetite, fatigue, vomiting, abdominal pain, and jaundice should be reported to a physician immediately during treatment. This medication should not be used in patients with certain blood disorders, severely impaired kidney function, and nursing women. Moreover, it is not recommended for children under 2 years of age as safety has not been established. Care should be taken when administering it to elderly patients or small children, and if severe rashes or allergic reactions occur on the skin, the medication should be discontinued immediately. Special care is required for patients with psoriasis or systemic lupus erythematosus when using this medication. In addition to liver function, regular blood tests are necessary while taking this medication, as there may occasionally be serious skin reactions, muscle pain, or decreased blood pressure. Such symptoms should be discussed with medical personnel immediately. Be cautious, as dizziness may occur while driving or operating machinery. There may be interactions if taken with other medications, so it is essential to inform your doctor or pharmacist if you are currently taking any other medications. Women who are pregnant or may become pregnant should carefully consider the risks and benefits before using this medication, and nursing women should stop breastfeeding during treatment. Overdosing may cause symptoms such as headache, nausea, abdominal pain, dizziness; in such cases, appropriate treatment should be sought immediately at a medical facility. This medication should be kept out of reach of children and stored at room temperature away from direct sunlight.

Side effects

Liver and biliary tract failure, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, malaise, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reaction, mucocutaneous syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, blistering dermatitis, psoriasiform rash, exacerbation of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, increased CPK, rhabdomyolysis, hypotension, dyspnea, chest tightness, urticaria, erythema, facial swelling, lymphangiectasis, abdominal distension, decreased appetite, dyspepsia, nausea, mild abdominal pain, diarrhea, discomfort in the stomach, thirst, vomiting, glossitis, depression, anxiety, headache, taste disturbance, dizziness, drowsiness, paresthesia, loss of sensation, decreased attention, insomnia, elevated BUN, frequency of urination, visual disturbances, tinnitus, anaphylactic-like reaction, angioedema, systemic lupus erythematosus, elevated total cholesterol levels, increased triglyceride levels, malaise, discoloration of the tongue, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, decreased vision, hearing loss, auditory impairment, vasculitis, permanent loss of smell, hyposmia, drug rash with eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, increased serum creatine phosphokinase, headache, nausea, upper abdominal pain, dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture. It should be stored in a tightly sealed container. The storage temperature should be maintained between 1 to 30 degrees Celsius. Proper storage can help maintain the medication's effectiveness and safety for a long time.

Appearance and packaging

Appearance

White to nearly off-white round tablets

Package unit

30 tablets/bottle, 150 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.